Kathy Wong

→ Jacob Elkins has left Sarepta to take the CMO job at AIRNA, the RNA editing shop that disclosed a $155 million Series ...

After 17 years at Genentech, Ira Mellman is joining the Parker Institute for Cancer Immunotherapy as president of research. The PICI, founded by tech entrepreneur Sean ...

→ Camilla Sylvest has moved on from Novo Nordisk after 28 years with the Danish pharma, including more than seven years as EVP of commercial strategy & corporate affairs. In ...

John McHutchison started Monday as CEO and chairman of Tune Therapeutics, after sitting on the company’s board for two years. One message he wants to make ...

William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins Immunocore board, exits Obsidian board.

→ Spark co-founder Kathy High made a quiet return to eye disease drug development, becoming CEO of US-Swiss biotech RhyGaze “late last year,” the Philadelphia Business Journal

The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo Fontoura as its chief medical officer and internally promoting co ...

TORL BioTherapeutics, the antibody-drug conjugate startup led by former Celgene chief Mark Alles, has brought aboard a chief medical officer with big pharma chops. Aran Maree will be overseeing clinical ...

Adi Hoess describes himself as someone who “likes to build” companies focused on “challenging technologies.” It’s fitting, then, that after spending more than a decade as CEO of German biotech ...

→ Eli Lilly has joined the club of pharma companies that have lined up AI execs. Thomas Fuchs will be Lilly’s first-ever chief AI officer on Oct. 21 and comes ...

→ Kristen Mulholland will take over for the retiring Peter Fasolo as chief human resources officer at J&J on Oct. 1. “Peter has led J&J’s talent strategy for the past ...

→ Bill Haney's Dragonfly Therapeutics has brought aboard Susan Altschuller as CFO. Altschuller's résumé includes other finance chief roles at Cerevel Therapeutics and ImmunoGen, which were ...

Ken Song is back in business. He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to IPO in three years, and then a $4.1 billion exit ...

→ Bill Haney has helped Skyhawk Therapeutics stand out in the wave of biotechs looking to drug RNA, taking over from fellow co-founder Kathleen McCarthy early in its history and ...

→ A spokesperson for Pfizer tells Peer Review that Michael Diem has joined the pharma giant as head of venture capital & equity investments. The AstraZeneca and GSK alum had ...

→ For the first time since he sold Celgene to Bristol Myers Squibb for $74 billion in 2019, Mark Alles is a CEO again. Alles had been chairing the board ...

Ash­ley Ma­g­a­rgee will be­come the CEO of Genen­tech on Jan. 1, two decades in­to her tenure at the South San Fran­cis­co biotech pi­o­neer, which she joined pri­or to its $47 bil­lion deal with now-par­ent Roche. She’s held the in­ter­im post since Nov. 1, when Alexan­der Hardy left in a sur­prise move to take the same post at Bio­Marin. Ma­g­a­rgee will re­port to the CEO of Roche Phar­ma, Tere­sa Gra­ham, who her­self worked up the cor­po­rate lad­der of Genen­tech and Roche on a sim­i­lar…

Alexan­dra Glucks­mann is al­ways look­ing for “the next fron­tier” in med­i­cine. Af­ter spend­ing most of her ca­reer in ge­net­ic dis­eases, rare dis­eases and on­col­o­gy, her next pur­suit is in men­tal health. The long­time bio­phar­ma ex­ec­u­tive is the next CEO at Sen­so­ri­um Ther­a­peu­tics, a biotech lever­ag­ing ma­chine learn­ing to de­vel­op new men­tal health treat­ments, start­ing from plant com­po­nents that are known to be psy­choac­tive. The com­pa­ny’s lead pro­gram in anx­i…

→ With Amy­lyx Phar­ma­ceu­ti­cals’ ALS drug in full com­mer­cial swing, the Mass­a­chu­setts start­up has found a re­place­ment for its chief med­ical of­fi­cer. Camille Bedrosian will join the com­pa­ny from Ul­tragenyx, tak­ing the place of Patrick Yerami­an, whose re­tire­ment was an­nounced in De­cem­ber 2022. Bedrosian has made a ca­reer in rare dis­ease drug de­vel­op­ment, hav­ing pre­vi­ous­ly worked not on­ly at Ul­tragenyx but al­so Alex­ion, where she was al­so the CMO. The rare dis­…

→ Cen­tu­ry Ther­a­peu­tics an­nounced the de­par­ture of CEO La­lo Flo­res in April, and the Philadel­phia cell ther­a­py biotech has found his suc­ces­sor. Brent Pfeif­f­en­berg­er just spent the last two years as COO of Neo­gene Ther­a­peu­tics, the US/Dutch TCR spe­cial­ist that’s now a sub­sidiary of As­traZeneca, and he led the US on­col­o­gy busi­ness at the tail end of an 18-year ca­reer with Bris­tol My­ers Squibb. Chaired by ex-No­var­tis chief Joe Jimenez, Cen­tu­ry elim­i­nat­ed 25%…